Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Myriad Genetics Inc
(NQ:
MYGN
)
26.23
+0.14 (+0.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Myriad Genetics Inc
< Previous
1
2
3
4
5
6
7
Next >
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
July 24, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
July 06, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Cramer Calls Tech Giant A 'Great' Long-Term Play, But In The Short Term It's Just 'Too Hot'
June 22, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said British American Tobacco p.l.c. (NYSE: BTI) is a "cheap stock. I’ll tell you, I actually like some of the things that Philip Morris International...
Via
Benzinga
Where Myriad Genetics Stands With Analysts
May 23, 2023
Via
Benzinga
Where Myriad Genetics Stands With Analysts
May 04, 2023
Via
Benzinga
3 Gene Testing Stocks to Buy Before They Take Off
June 17, 2023
The future of gene testing is bright thanks to an aging population. Here are three companies leading the industry.
Via
InvestorPlace
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
June 12, 2023
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
June 07, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
June 01, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
May 31, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
May 24, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 23, 2023
Gainers
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2023
May 23, 2023
Via
Benzinga
Lilium, Myriad Genetics And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
May 23, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Exact Sciences Serves Investors Exactly What They Wished For
May 15, 2023
Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The
Via
MarketBeat
Myriad Genetics Earns 2023 Great Place to Work Certification™
May 08, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
May 03, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Why Atlassian Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 05, 2023
Gainers
Via
Benzinga
Myriad Genetics to Participate in BofA Securities Healthcare Conference
May 02, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
April 26, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
April 19, 2023
Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Intermountain Precision Genomics and Myriad Genetics Now Offer Solid Tumor Testing in All 50 States
April 18, 2023
About Intermountain Health Headquartered in Utah with locations in seven states and additional operations across the western U.S., www.intermountainhealth.org is a nonprofit system of 33 hospitals, 385...
Via
PRUnderground
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
April 18, 2023
Intermountain Precision Genomics Laboratory receives certification from NYS Department of Health Clinical Laboratory Evaluation Program
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
April 12, 2023
New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient care
From
Myriad Genetics, Inc.
Via
GlobeNewswire
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
March 25, 2023
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.
Via
InvestorPlace
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
March 02, 2023
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry
From
Myriad Genetics, Inc.
Via
GlobeNewswire
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
March 01, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 01, 2023
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
Via
Benzinga
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
March 01, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
February 28, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.